(SIBN) Si-Bone - Ratings and Ratios
Implants, Screws, Plates, Instruments
SIBN EPS (Earnings per Share)
SIBN Revenue
Description: SIBN Si-Bone October 22, 2025
SI-BONE, Inc. (NASDAQ: SIBN) develops and sells minimally invasive implant systems that treat sacroiliac (SI) joint dysfunction, pelvic trauma, and related spinal-fusion indications. Its product portfolio centers on the iFuse family-including iFuse-3D (a 3-D-printed porous titanium implant), iFuse TORQ (threaded trauma implants), iFuse Bedrock Granite (fusion and fixation platform), and iFuse INTRA (cell-based therapies)-which it markets primarily through a direct sales force supplemented by third-party agents.
Founded in 2008 and headquartered in Santa Clara, California, SI-BONE operates in the U.S. and select international markets. The company is classified under GICS “Health Care Supplies” and focuses on the niche but growing sacropelvic device segment, which analysts estimate to be a $1.5 billion market globally, driven by an aging population and rising rates of low-back pain diagnoses.
Recent financials show FY 2023 revenue of approximately $150 million, representing a 22 % year-over-year increase, while gross margins have hovered near 78 %-a level typical for high-margin implant manufacturers. The firm’s pipeline includes a next-generation 3-D-printed SI joint implant slated for FDA clearance in 2025, which could expand its addressable market by an estimated 15 % if reimbursement pathways remain favorable.
Given the company’s strong margin profile, expanding product pipeline, and the broader macro trend of increasing minimally invasive spine procedures, a closer look at its valuation multiples and cash-flow outlook is warranted; the ValueRay platform offers a concise dashboard that can help you assess whether SIBN’s current price reflects its growth potential.
SIBN Stock Overview
| Market Cap in USD | 658m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2018-10-17 |
SIBN Stock Ratings
| Growth Rating | -6.01% |
| Fundamental | 40.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -3.04% |
| Analyst Rating | 4.56 of 5 |
SIBN Dividends
Currently no dividends paidSIBN Growth Ratios
| Growth Correlation 3m | -50.3% |
| Growth Correlation 12m | 32.9% |
| Growth Correlation 5y | -64.4% |
| CAGR 5y | -5.10% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.09 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.15 |
| Sharpe Ratio 12m | -0.37 |
| Alpha | 7.31 |
| Beta | 0.838 |
| Volatility | 48.10% |
| Current Volume | 281.7k |
| Average Volume 20d | 355.8k |
| Stop Loss | 14.3 (-5.6%) |
| Signal | 0.37 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-23.8m TTM) > 0 and > 6% of Revenue (6% = 11.1m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA 6.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 98.62% (prev 119.6%; Δ -21.00pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -3.26m > Net Income -23.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (42.8m) change vs 12m ago 3.56% (target <= -2.0% for YES) |
| Gross Margin 79.45% (prev 77.69%; Δ 1.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 81.48% (prev 67.33%; Δ 14.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.91 (EBITDA TTM -15.8m / Interest Expense TTM 3.00m) >= 6 (WARN >= 3) |
Altman Z'' -9.38
| (A) 0.79 = (Total Current Assets 207.4m - Total Current Liabilities 24.8m) / Total Assets 230.9m |
| (B) -1.92 = Retained Earnings (Balance) -444.0m / Total Assets 230.9m |
| warn (B) unusual magnitude: -1.92 — check mapping/units |
| (C) -0.09 = EBIT TTM -20.8m / Avg Total Assets 227.4m |
| (D) -7.32 = Book Value of Equity -443.4m / Total Liabilities 60.6m |
| Total Rating: -9.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.27
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -2.32% = -1.16 |
| 3. FCF Margin -6.87% = -2.58 |
| 4. Debt/Equity 0.22 = 2.48 |
| 5. Debt/Ebitda -0.18 = -2.50 |
| 6. ROIC - WACC (= -16.77)% = -12.50 |
| 7. RoE -14.20% = -2.37 |
| 8. Rev. Trend 96.53% = 7.24 |
| 9. EPS Trend 93.04% = 4.65 |
What is the price of SIBN shares?
Over the past week, the price has changed by -1.81%, over one month by +6.92%, over three months by -14.89% and over the past year by +15.03%.
Is Si-Bone a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SIBN is around 13.34 USD . This means that SIBN is currently overvalued and has a potential downside of -11.95%.
Is SIBN a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SIBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.8 | 63.6% |
| Analysts Target Price | 24.8 | 63.6% |
| ValueRay Target Price | 14.9 | -1.7% |
SIBN Fundamental Data Overview October 31, 2025
P/S = 3.5535
P/B = 3.6241
Beta = 0.838
Revenue TTM = 185.3m USD
EBIT TTM = -20.8m USD
EBITDA TTM = -15.8m USD
Long Term Debt = 35.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.11m USD (from shortTermDebt, last quarter)
Debt = 36.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78m USD (from netDebt column, last quarter)
Enterprise Value = 549.7m USD (658.3m + Debt 36.9m - CCE 145.5m)
Interest Coverage Ratio = -6.91 (Ebit TTM -20.8m / Interest Expense TTM 3.00m)
FCF Yield = -2.32% (FCF TTM -12.7m / Enterprise Value 549.7m)
FCF Margin = -6.87% (FCF TTM -12.7m / Revenue TTM 185.3m)
Net Margin = -12.83% (Net Income TTM -23.8m / Revenue TTM 185.3m)
Gross Margin = 79.45% ((Revenue TTM 185.3m - Cost of Revenue TTM 38.1m) / Revenue TTM)
Gross Margin QoQ = 79.80% (prev 79.71%)
Tobins Q-Ratio = 2.38 (Enterprise Value 549.7m / Total Assets 230.9m)
Interest Expense / Debt = 1.80% (Interest Expense 666.0k / Debt 36.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -16.4m (EBIT -20.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.38 (Total Current Assets 207.4m / Total Current Liabilities 24.8m)
Debt / Equity = 0.22 (Debt 36.9m / totalStockholderEquity, last quarter 170.3m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 2.78m / EBITDA -15.8m)
Debt / FCF = -0.22 (negative FCF - burning cash) (Net Debt 2.78m / FCF TTM -12.7m)
Total Stockholder Equity = 167.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.29% (Net Income -23.8m / Total Assets 230.9m)
RoE = -14.20% (Net Income TTM -23.8m / Total Stockholder Equity 167.4m)
RoCE = -10.23% (EBIT -20.8m / Capital Employed (Equity 167.4m + L.T.Debt 35.5m))
RoIC = -8.08% (negative operating profit) (NOPAT -16.4m / Invested Capital 203.0m)
WACC = 8.69% (E(658.3m)/V(695.3m) * Re(9.10%) + D(36.9m)/V(695.3m) * Rd(1.80%) * (1-Tc(0.21)))
Discount Rate = 9.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.69%
Fair Price DCF = unknown (Cash Flow -12.7m)
EPS Correlation: 93.04 | EPS CAGR: 165.2% | SUE: 4.0 | # QB: 3
Revenue Correlation: 96.53 | Revenue CAGR: 24.82% | SUE: 0.51 | # QB: 0
Additional Sources for SIBN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle